escitalopram + peginterferon alfa-2a + ribavirin

This is a combination therapy consisting of three drugs: - Escitalopram, a selective serotonin reuptake inhibitor (SSRI) antidepressant. - Peginterferon alfa-2a, a pegylated form of interferon alpha used as an immunomodulator and antiviral agent. - Ribavirin, a nucleoside analog antiviral medication. Escitalopram acts by selectively inhibiting the reuptake of serotonin in the central nervous system, increasing its availability and improving mood. Peginterferon alfa-2a binds to cell surface receptors to induce antiviral, antiproliferative, and immunomodulatory activities through the JAK/STAT signaling pathway. Ribavirin inhibits viral RNA synthesis and viral mRNA capping by mimicking natural nucleosides. The combination of peginterferon alfa-2a and ribavirin is standard for treating chronic hepatitis C virus (HCV) infection[1][2][3]. Escitalopram may be co-administered in this regimen to manage or prevent depression associated with interferon-based therapies. This triple-drug regimen is not marketed as a fixed-dose product but may be used together in clinical practice for patients requiring both HCV treatment and management of psychiatric symptoms.